Ethical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?

Benzer Materyaller

• Clearing Muddy Waters: The Need to Reconceptualize Minor Increase over Minimal Risk in Pediatric Rare Disease Research
  Yazar:: Duenas, Devan M., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Greater Than Minimal Risk, No Direct Benefit – Bridging Drug Trials and Novel Therapy in Pediatric Populations
  Yazar:: Wilfond, Benjamin S., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Conflicts of Interest and Recommendations for Clinical Treatments That Benefit Researchers
  Yazar:: Wilfond, Benjamin S., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Click Here to Complete This Survey: Online Research, Adolescents, and Parental Consent
  Yazar:: Johnson, Liza-Marie, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Selective Cooperation in Early Childhood – How to Choose Models and Partners
  Yazar:: Hermes, Jonas, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)